Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Chen L, Wang Y, Cai C, Ding Y, Kim RS, Lipchik C, Gavin PG, Yothers G, Allegra CJ, Petrelli NJ, Suga JM, Hopkins JO, Saito NG, Evans T, Jujjavarapu S, Wolmark N, Lucas PC, Paik S, Sun M, Pogue-Geile KL, Lu X. Chen L, et al. Among authors: allegra cj. J Clin Oncol. 2024 May 1;42(13):1520-1530. doi: 10.1200/JCO.23.01080. Epub 2024 Feb 5. J Clin Oncol. 2024. PMID: 38315963
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: allegra cj. Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: allegra cj. Breast Cancer Res. 2024 May 24;26(1):83. doi: 10.1186/s13058-024-01833-6. Breast Cancer Res. 2024. PMID: 38790033 Free PMC article. No abstract available.
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
George TJ, Lee JH, DeRemer DL, Hosein PJ, Staal S, Markham MJ, Jones D, Daily KC, Chatzkel JA, Ramnaraign BH, Close JL, Ezenwajiaku N, Murphy MC, Allegra CJ, Rogers S, Zhang Z, Li D, Srinivasan G, Shaheen M, Hromas R. George TJ, et al. Among authors: allegra cj. JCO Precis Oncol. 2024 Dec;8:e2400406. doi: 10.1200/PO-24-00406. Epub 2024 Dec 3. JCO Precis Oncol. 2024. PMID: 39626160 Free PMC article. Clinical Trial.
NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.
Kennecke HF, Auer R, Cho M, Dasari NA, Davies-Venn C, Eng C, Dorth J, Garcia-Aguilar J, George M, Goodman KA, Kreppel L, Meyer JE, Monzon J, Saltz L, Schrag D, Smith JJ, Zell JA, Das P; National Cancer Institute Rectal-Anal Task Force. Kennecke HF, et al. J Natl Cancer Inst. 2023 Dec 6;115(12):1457-1464. doi: 10.1093/jnci/djad143. J Natl Cancer Inst. 2023. PMID: 37535679 Free PMC article.
The New NCI Precision Medicine Trials.
Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH. Harris LN, et al. Among authors: allegra cj. Clin Cancer Res. 2023 Dec 1;29(23):4728-4732. doi: 10.1158/1078-0432.CCR-23-0917. Clin Cancer Res. 2023. PMID: 37531248 Free PMC article.
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
Wagman LD, Geller DA, Jacobs SA, Petrelli NJ, Allegra CJ, Lipchik C, Pogue-Geile KL, Srinivasan A, Wang Y, O'Connell MJ; NSABP FC-6 Study Group. Wagman LD, et al. Among authors: allegra cj. J Surg Oncol. 2022 Dec;126(8):1494-1503. doi: 10.1002/jso.27078. Epub 2022 Sep 16. J Surg Oncol. 2022. PMID: 36111443
233 results